Kornimate/medical-research-clean huggingface dataset:
the effects of stair climbing on arterial stiffness, blood pressure and leg strength in stage-1 postmenopausal women

Conditions: Hypertension; Menopause

Summary: we used a parallel experimental design. following an initial screening and familiarization session of study tests and procedures, eligible postmenopausal women were randomly assigned to a stair climbing (sc) group or non-exercising control group. sc training session was progressive program, and was performed 4 days a week for 12 weeks. measurements were collected at baseline and after 12 weeks during the same time of day (±1 hour) in the morning following an overnight fast and abstinence from caffeinated drinks, alcohol, and between 48 and 72 hours after the last exercise session.


Eligibility criteria:
inclusion criteria: * stage-1 hypertension * postmenopausal exclusion criteria: * pulmonary, renal, adrenal, pituitary, severe psychiatric, thyroid, or cardiovascular disease other than stage-1 systolic hypertension (140-159 mmhg) * hormone replacement therapy during the 6 months prior the study * smoker or having any medication changes in the previous year * experience with psychological and physical therapy in the previous year * history of steady exercise or exercise training in the last year
a phase iii study of a01016 in subjects with symptomatic vitreomacular adhesion

Conditions: Symptomatic Vitreomacular Adhesion

Summary: the purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (vma) resolution of a single intravitreal injection of a01016 (ocriplasmin) compared to sham-injection in subjects with symptomatic vma.


Eligibility criteria:
inclusion criteria: * symptomatic vitreomacular adhesion (vma) which, in the opinion of the investigator, is related to decreased visual function; * best corrected visual acuity (bcva) of 20/25 or worse in the study eye; * bcva of 20/800 or better in the non-study eye; * provide written informed consent; * follow specified instructions during study period; * other protocol-defined inclusion criteria may apply. exclusion criteria: * evidence of proliferative retinopathy, exudative age-related macular degeneration, or retinal vein occlusion in the study eye; * vitreous hemorrhage or other opacification; * high myopia in the study eye; * ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior 3 months; * uncontrolled glaucoma in the study eye; * history of retinal detachment in either eye; * active infection in either eye; * pregnant or of child-bearing potential and not utilizing acceptable form of contraception; * participation in another investigational drug study within 30 days prior to this study; * other protocol-defined exclusion criteria may apply.

Keywords: vitreomacular adhesion vitreomacular traction vitreomacular traction syndrome vitrectomy central visual field defect blind spot intravitreal injection macula retina decreased visual acuity visual complaint sd-oct macular hole
the effect of beer, red wine and fruit juice on blood vessel function in persons with cardiovascular disease

Conditions: Coronary Heart Disease

Summary: to study the effect of red wine, beer and fruit juice on endothelial function in patients with coronary heart disease.


Eligibility criteria:
inclusion criteria: * men or postmenopausal women with stable coronary heart disease * coronary heart disease should be verified by coronary angiography with at least 50% stenosis in at least one coronary vessel. exclusion criteria: * patients with myocardial infarction within the last tree months * persons with a present or earlier alcohol abuse * persons with a present or earlier drug abuse * person with malign disease * persons, that we consider unsuitable to carry through the examines.

Keywords: alcohol red wine endothelial function flow-mediated vasodilation cardiovascular disease
natural history of the progression of choroideremia study

Conditions: Choroideremia

Summary: the objective of this natural history study is to gain a better understanding of the progression of choroideremia (chm) and add to the knowledge base for this rare disease.

this study was previously posted by nightstarx ltd. in october 2020, sponsorship of the trial was transferred to biogen.

Eligibility criteria:
key inclusion criteria: * are willing and able to provide informed consent for participation in the study. * have a clinical phenotype and confirmed genetic diagnosis of chm. * have active disease clinically visible within the macular region. * are willing and able to undergo ophthalmic examinations once every 4 months for up to 20 months. * have a bcva better than or equal to 6/60 (20/200; decimal 0.1; logmar 1.0; 34-38 etdrs letters) in at least one eye. key exclusion criteria: * have a history of amblyopia in the eligible eye. * have any other significant ocular or non-ocular disease/disorder in the eligible eye which, in the opinion of the investigator, may put the subject at risk because of participation in the study, influence the results of the study or influence the subject's ability to participate in the study. * have participated in an interventional research study in the past 6 months. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: rep1 retina retinal degeneration retinal dystrophy natural history
ultrasonographic response to polarized light therapy in the treatment of atopic dermatitis

Conditions: Chronic Atopic Dermatitis

Summary: non-atopic dermatitis (nad) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. it is usually seen in childhood, but can onset within or persist into adulthood.

polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions. 40 male patients who had atopic dermatitis in the chronic stage, they were complaining from itching, inflammation and skin thickness in the arm, wrist, hand and leg will participate in this study.

Eligibility criteria:
inclusion criteria: * the patients' ages will ranged from 20 to 30 years. * the subjects will be males. * the duration of disease less than 1 year. exclusion criteria: * patients who had skin malignancy in the area to be treated. * the patients who had history of diabetes, circulatory or sensory disorders. * patients with acute infection in the area treated.
calf muscle tightness in flat foot subjects

Conditions: Flat Feet

Summary: the purpose of the current work is to determine the prevalence of calf muscle tightness in asymptomatic flat foot subjects.

pes planus (flat foot) deformity is a common chronic foot and ankle condition characterized by flattening of the medial longitudinal arch (mla), rearfoot valgus and abduction of the midfoot on the hind foot. a flexible pes planus is caused by tibialis posterior dysfunction, ligament loosening, achilles tendon shortening, and weakness of the intrinsic foot muscles. these deformations cause plantar flexion and adduction of the talus bone and valgus of the calcaneus bone. up to our knowledge: 1. no previous studies investigated whether all flat foot is usually associated with gastrocnemius and soleus muscle tightness or it is a random association. 2. and whether tightness of gastrocnemius and soleus is highly found in all cases of flat foot. consequently this study is conducted.

Eligibility criteria:
inclusion criteria: 1. subjects should have flexible flat foot. 2. age between 20 and 40 years. 3. navicular drop of more than 10 mm. 4. body mass index from 18.5 kg/m2 to 29.9 kg/m2. 5. subjects will sign the written consent form after the aim and methods of the study are explained clearly. exclusion criteria: 1. subjects with history of foot and ankle surgery, trauma, fracture or dislocation. 2. subjects with congenital deformities in the ankle and foot. 3. subjects with systemic or neurologic diseases that could affect lower extremity biomechanics.
role of auditory cortical oscillations in speech processing and dyslexia

Conditions: Dyslexia

Summary: this study aims at investigating the role of low-gamma activity in phonemic encoding and its implication in dyslexia. indeed, a phonological deficit, i.e. a difficulty in perceiving the sounds of speech, is strongly suspected in dyslexia but has never been conclusively associated with a specific underlying mechanism. the study employs transcranial alternating current stimulation in adults with and without dyslexia to exploit the effect of the stimulation on phonemic processing and neural activity measured with electroencephalography. in doing so, it would be possible to establishing a causal link between gamma oscillations and the phonological deficit in dyslexia.


Eligibility criteria:
inclusion criteria: * 18-65 years old; * french native speakers; * normally-hearing; * intellectual quotient (iq) around average; * for the dyslexia group: previous diagnosis of dyslexia as assessed by a speech therapist. exclusion criteria: * presence of metal or electronic implants in the brain/skull; * presence of metal or electronic device at other in other parts of the body; * have experienced a seizure or a loss of consciousness or a severe head trauma; * severe brain related illness ; * intake of central nervous system-effective medication; * pregnant and nursing women; * relatives affected by epilepsy.
investigating patient satisfaction with oral anti-cancer treatment in patients with hormone-receptor positive, her2-receptor negative, advanced breast cancer

Conditions: ER Positive, HER2 Negative Breast Cancer Neoplasms

Summary: a prospective, non-interventional, non-controlled multicenter observational study to evaluate aspects of pharmaceutical care and the treatment of postmenopausal patients with hormone-receptor positive, her2-receptor negative, advanced breast cancer treated with everolimus and exemestane. the main objective of the study is to evaluate medication adherence in postmenopausal, hormone-receptor positive, her2-receptor negative, advanced breast cancer treated with a combination of everolimus and exemestane. additionally, other aspects of the pharmacotherapy, with focus on the patient perspective, will be investigated: * patient satisfaction with treatment information * patient satisfaction with treatment * health-related quality of life * treatment efficacy * treatment-related toxicity * patient follow-up by the oncologic team/general practitioner and or specialized home nurses this study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.


Eligibility criteria:
inclusion criteria: * postmenopausal women, 18 years or older * signed written informed consent * patient can be contacted by phone and/or e-mail * hr+, her2- advanced or metastatic breast cancer * recurrence or progression following a non-steroidal aromatase inhibitor * able to swallow and retain oral medication * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 exclusion criteria: * patients who are not able to understand dutch or french * symptomatic visceral metastatic disease * patients who have taken an investigational drug within 28 days or 5 half-lives, whichever is shorter, prior to recruitment * current use of a prohibited medication as described in the spc * any serious or unstable pre-existing medical conditions, psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedure * hypersensitivity to the active substances or to any of the excipients
promoting health during pregnancy: a multiple behavior computer tailored intervention

Conditions: Life Stress; Smoking Cessation; Poor Nutrition

Summary: this program of research tested the effectiveness of an ipad delivered multiple behavior intervention grounded in the transtheoretical model of behavior change for pregnant women. it was hypothesized that the intervention would reduce the number of health behavior risks reported by pregnant women in the treatment group. the target behaviors of the intervention are smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption.

promoting health behaviors during pregnancy has tremendous public health significance. poor health behaviors are associated with pregnancy complications, birth outcomes, and the health of the child. they influence infant birthweight, premature birth, and infant mortality rates, all of which continue to be public health concerns, reflected in the goals of healthy people 2020. pregnant women, particularly those from under-served populations, often have a multitude of health behavior risks that threaten positive pregnancy and birth outcomes, as well as the future health of mother and baby. pregnancy offers a window of opportunity for behavioral intervention. the immediate health risk for the baby motivates most pregnant women to at least consider changing their behavior. furthermore, the regular and continual medical care that most pregnant women receive allows optimal access for intervention. the circumstance of pregnancy can be used as a teachable moment to better the future health of women and children. the primary goals of this study were to complete and enhance the development of an ipad delivered intervention and to assess the efficacy in a randomized clinical trial involving pregnant women from three federally-funded community health centers that treat under-served populations. using interactive technology, users complete onscreen assessments and receive individually tailored feedback messages on key behavior change strategies identified by the transtheoretical model of behavior change and matched to their stage of readiness for each behavior. supplemental intervention components were created including printed feedback reports, a multiple behavior stage-based manual, and spanish versions of all intervention materials. this intervention offers a cost-effective, science based, and easily deliverable solution to improve multiple health behaviors, and overall health and well-being, of populations of pregnant women.

Eligibility criteria:
inclusion criteria: * at least 18 years old * speak and read either english or spanish * consent to the research. exclusion criteria: * more than 18 weeks gestation
a survey to evaluate diabetes management, control, chronic complications, psychosocial aspects of diabetic subjects in korea

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in asia.


Eligibility criteria:
inclusion criteria: * diabetic patients registered in the particular centre for more than 12 months. * patients should have visited the centre at least once in the last 3-6 months apart from the initial visit. * patients willing to sign informed consent form. exclusion criteria: * repetition of any patient as patients should not be included twice for any reason. * unwilling to participate or unable to comply with protocol requirements.
clinical observation of the transscleral suture fixation of posterior chamber intraocular lens in eyes with inadequate capsule support

Conditions: Absence of Capsule Support; Aphakia

Summary: to present the follow-up outcomes of transscleral suture fixation of posterior chamber intraocular lens (pciol) in eyes with inadequate capsule support.


Eligibility criteria:
inclusion criteria: 1. patients who underwent transscleral suture fixation of pciol 2. time between the primary surgeries was at least 3 months exclusion criteria: 1. active intraocular inflammation 2. the intraocular pressure (iop) was higher than 25 mmhg 3. the endothelial cell count (ecc) was more than 1,200 cells/mm2
study to compare the the analgesic efficacy and tolerability of meloxicam versus placebo and ibuprofen in the treatment of pain after surgery of the third molar

Conditions: Pain

Summary: to assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an observation period of 6 hours in the treatment of pain after surgery of the third molar.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or above * patients undergoing removal of one impacted mandibular third molar under local anesthesia. (short duration anaesthetics will be allowed, i.e. mepivacaine 3% in italy and spain and xylocaine in usa, both without vasoconstrictors) only patients with type of inclusion ii to iv have to be included (type ii, molar in the submucosa; type iii, molar partially included in the bone; type iv, molar fully included in the bone) * assessment of pain must be at least 50 mm on a 100 mm visual analogue scale (vas) * patient informed consent in accordance with local legislation. exclusion criteria: * type i of inclusion (molar partially or totally erupted) * known or suspected hypersensitivity to trial drug or their excipients, analgesics, antipyretics or nonsteroidal antiinflammatory drug (nsaids) * any clinical evidence of active peptic ulceration during the last six month * recurrent ulcers * pregnancy or breast feeding * asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or nsaids * concomitant treatment with anti-coagulants (including heparin), lithium * concomitant administration of other anti inflammatory or analgesic agents * administration of any drug with analgesic properties in the 24 h previous to the administration of the study drug, except the local anesthetic for the surgery * administration of any antibiotics * significant perioperative complication judged by the oral surgeon * clinical evidence of or known severe cardiac, hepatic, renal, metabolic, hematological disease (including bleeding disorders), mental disturbance, ulcerative colitis * any other disease that could interfere with the evaluation of efficacy and safety * participation in another clinical trial during this study or during the previous month * previous participation in this trial * patient unable to comply with the protocol
effects of vitamin d supplementation during pregnancy on clinical outcomes and immune function

Conditions: Vitamin D Deficiency

Summary: researchers at the usda western human nutrition research center and clinicians at uc davis medical center are currently conducting a study on the effects of vitamin d supplementation during pregnancy on maternal health and immune function. the investigators believe that vitamin d supplementation at levels greater than the current recommendation is beneficial for maternal health during pregnancy. in particular, there is evidence that vitamin d deficiency during pregnancy puts women at greater risk for diseases like pre-eclampsia, which may be due to an imbalance in immune function at the placenta. this randomized, double-blind study is designed to test this hypothesis. pregnant women who participate in the study receive either 400 iu or 2,000 iu of vitamin d per day for the duration of their pregnancy. the investigators will collect blood at three time points during pregnancy (16-20 weeks, 26-28 weeks, 36 weeks gestation) for analysis of immune function and vitamin d status. the investigators are also collecting data on clinical parameters, such as blood pressure and glucose tolerance.


Eligibility criteria:
inclusion criteria: * pregnant women * less than 20 weeks gestation * over 18 years of age * able to swallow nutritional supplements exclusion criteria: * use of medications known to affect vitamin d metabolism * diagnosis of type 1 diabetes * history of thyroid, renal, or liver disease * problems with digestion or absorption

Keywords: pregnancy immune function
to evaluate the inflammatory markers in adult patients with asthma associated with allergic rhinitis receiving montelukast therapy (0476-366)

Conditions: Asthma

Summary: to evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from peripheral blood after newly initiated montelukast therapy.


Eligibility criteria:
inclusion criteria: * allergic rhinitis symptoms: sneezing, rhinorrhea, obstruction of the nasal passages, itchy nose and throat, and conjunctival * male or female outpatient 20 years of age and older * patients with the following signs and symptoms of asthma and allergic rhinitis: history of cough, wheezing, shortness of breath, positive methacholine bronchoprovocation test exclusion criteria: * active, acute or chronic, pulmonary disorder (besides asthma) documented by history, physical examination, or chest x-ray. history of anaphylactic or hypersensitive to study drug * requires oral, intravenous, or intramuscular corticosteroids on daily routine basis * started on immunotherapy within six months before the pre-study visit and/or the dose of immunotherapy is expected to change over the course of the study * treated with montelukast within 3 months before enrollment * unable to perform acceptable, reproducible spirometry and peak flow measurement * unresolved symptoms and signs of an upper respiratory tract infection (uri) within 2 weeks prior to visit 1
tnths predicting evolving non-stemi

Conditions: Acute Coronary Syndrome

Summary: background: we sought to determine the diagnostic value of the new tnths assay for early detection of evolving non-stemi in patients with acute coronary syndrome and a negative 4th generation ctnt result on admission. methods: we evaluated several statistical patterns of blood results of tnt hs and ctnt of 115 patients and calculated necessity of prediction of evolving non-stemi within 6 hours. results: based on the results of the 4th generation ctnt assay, an evolving non-stemi was diagnosed in 26 patients, 31 were classified as unstable angina. the tnths lead to an increase of non-stemi diagnosis as compared to the 4th generation assay. we could calculate increased sensitivities for earlier detection of evolving non-stemi from 61.5% on admission to 90.9% within 3 hours and 100% within 6 hours compared to ctnt. conclusions: the tnths assay enables earlier detection of non-stemi and allows identification of an additional percentage of cases with non-stemi previously classified as unstable angina.


Eligibility criteria:
inclusion criteria: * 115 consecutive patients were enrolled with symptoms suggestive of acs, admitted to the chest pain unit of the university of heidelberg. all patients received a 12-lead electrocardiogram (ecg) recording on admission, and a second 12-lead ecg after 6 hours exclusion criteria: * patients who underwent percutaneous coronary intervention (pci) during follow-up sampling were excluded as were patients with a significant kidney dysfunction defined as an estimated glomerular filtration rate below 60 ml/min/1.73m2. * patients with stemi were excluded. * patients with only 1 blood sample were also excluded.

Keywords: high sensitive troponin t; non-stemi; early detection. to detect non-stemi in a cohort of patients with acute coronary syndrome